Literature DB >> 10639606

Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy.

S Ponsford1, H Willison, J Veitch, R Morris, P K Thomas.   

Abstract

The incidence of hematological malignancy in patients with monoclonal gammopathy of undetermined significance (MGUS) has been assessed as 17% to 25%. To ascertain whether this is true of neuropathy associated with MGUS, a long-term (5-42 years) retrospective clinical and neurophysiological follow-up was conducted in 50 cases (immunoglobulin M [IgM], n = 38; IgG, n = 11; IgA, n = 1). Only three patients developed hematological malignancy. Of 25 survivors with IgM paraproteinemia, 7 had myelin-associated glycoprotein antibodies with typical clinical features. Evoked distal muscle amplitudes were significantly smaller than for the other paraprotein classes. Preferential distal demyelination manifested by relative prolongation of distal motor latency was not apparent in the cases of long duration. Two patients with IgM antidisialosyl antibodies and cold agglutinating activity had a large fiber neuropathy with intermittent oculofacial involvement. Both responded to intravenous immunoglobulin. Findings in the remaining patients were varied. Recognition of IgM subgroups is important both for prognosis and possible response to treatment. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639606     DOI: 10.1002/(sici)1097-4598(200002)23:2<164::aid-mus4>3.0.co;2-y

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Authors:  Jean-Marc Léger; Karine Viala; Guillaume Nicolas; Alain Créange; Jean-Michel Vallat; Jean Pouget; Pierre Clavelou; Christophe Vial; Andreas Steck; Lucile Musset; Benoit Marin
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

Review 2.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

3.  Additional causes for distal sensory polyneuropathy in diabetic patients.

Authors:  K C Gorson; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

4.  Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?

Authors:  Pierre Lozeron; Vincent Ribrag; David Adams; Marion Brisset; Marguerite Vignon; Marine Baron; Marion Malphettes; Marie Theaudin; Bertrand Arnulf; Nathalie Kubis
Journal:  J Neurol       Date:  2016-06-17       Impact factor: 4.849

Review 5.  Treatment for IgG and IgA paraproteinaemic neuropathy.

Authors:  Abraham C J Stork; Michael P T Lunn; Eduardo Nobile-Orazio; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2015-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.